echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The R & D expenses of 101 pharmaceutical companies have been exposed, and the company spent 1.4 billion yuan in three months

    The R & D expenses of 101 pharmaceutical companies have been exposed, and the company spent 1.4 billion yuan in three months

    • Last Update: 2019-11-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] data shows that the average R & D investment of top 100 pharmaceutical industry in 2018 is 460 million yuan, accounting for 5.4% of the total More than 15% of the top three enterprises with high investment have reached the level of multinational pharmaceutical enterprises With the increase of R & D investment of various pharmaceutical enterprises, the R & D level of innovative drugs in China began to significantly improve In 2018, China drug Audit Center accepted 157 applications for registration of class 1 Chemical innovative drugs, with a slight increase compared with 2017 Recently, the disclosure of the third quarter performance report of the listed companies in 2019 has come to an end According to incomplete statistics, there are 101 listed pharmaceutical companies with R & D expenses of more than 50 million yuan in A-share and Hong Kong share, while the total R & D expenses of 101 pharmaceutical companies in the first three quarters of 2019 is about 28.214 billion yuan Among them, four pharmaceutical enterprises, Baiji Shenzhou, Hengrui, Fosun and Shiyao, totaled over 10 billion yuan; 8 pharmaceutical enterprises' R & D investment increased year-on-year, and 14 pharmaceutical enterprises' R & D investment accounted for more than 10% of business income, and Hengrui's R & D investment reached 66.97% The author specially collated the data of pharmaceutical companies with R & D investment of more than 1 billion to see how they achieved under the large amount of R & D investment Baiji Shenzhou: 4.524 billion yuan In the first three quarters of 2019, the R & D cost of Baiji Shenzhou increased by 52.79% year on year, accounting for 173.58% of the operating revenue, of which the R & D cost in the third quarter was 237 million dollars (about 1.665 billion yuan) At present, Baiji Shenzhou has submitted two class 1 new drug marketing applications in China, namely, tirelizumab injection (PD-1) and zambutinib capsule (Btk inhibitor), of which zambutinib has been approved by the US FDA on November 14, and tirelizumab has been updated to "in approval" status in China, which is on the way to market In addition, in November 1, Baiji Shenzhou also announced the establishment of a global cancer strategic cooperation relationship with Amgen, obtaining the sales rights and interests of three Amgen listed varieties, and jointly developing 20 Amgen anti-tumor pipeline drugs Amgen has agreed to buy a 20.5% stake in Baiji Shenzhou for about $2.7 billion, which is expected to be completed in early 2020 Hengrui pharmaceutical: 2.899 billion yuan In the first three quarters of this year, Hengrui pharmaceutical realized a revenue of 16.945 billion yuan, a year-on-year increase of 36.01%; among them, the R & D expense in the first three quarters increased by 66.97% year-on-year, accounting for 17.11% of the business revenue, and the R & D expense was 1.415 billion yuan In terms of innovative medicine, Hengrui medicine has entered the harvest period In 2018, pyrrolidine, thiopefigeristine (19K), albumin paclitaxel and other heavy-duty innovative drugs were approved for marketing In May 2019, the overweight product PD-1 carrelizumab was approved for marketing Moreover, since its launch in July, it has been increasing rapidly, which has driven the high growth of tumor line products In addition, the number of cancer drugs approved last year, such as albumin paclitaxel, pyrrolidine and 19K, is also on the rise In the first three quarters, Hengrui pharmaceutical added 4 new clinical applications for class 1 innovative drugs, including 2 class 1 chemical drugs and 2 class 1 biological drugs Up to now, the company has been approved five innovative drugs, and the total number of class 1 new drugs declared is nearly 50, far away in the domestic market The R & D field of the company takes tumor as the core, and expands to the fields of autoimmune, hypoglycemic, cardiovascular and so on In terms of the development of innovative drugs, Hengrui medicine basically has new drug applications every year, and every 2-3 years there will be a healthy development trend of new drug listing Fosun Pharmaceutical: 2.253 billion yuan The R & D expenses of Fosun Pharmaceutical in the first three quarters of 2019 increased by 20.7% year-on-year, accounting for 10.62% of the operating revenue, of which the R & D expenses in the third quarter were 903 million yuan As of August 26, Fosun Pharmaceutical Group has been engaged in 233 projects in the research of new drugs, generic drugs, biological similar drugs and generic drug consistency evaluation In addition, 23 projects were introduced, including 8 imported innovative drugs and 15 imported generic drugs Nine small molecule innovative drug products (including one modified new drug) and nine indications have been approved for clinical trials in China; one monoclonal antibody product has been listed in China, two monoclonal antibody products have been accepted for listing in China and all of them have been included in the priority review process, 13 monoclonal antibody products and three joint treatment schemes have been launched in the global scope More than 20 clinical trials were conducted Among them, the first heavyweight product of Fuhong Hanlin, hanlikang (rituximab injection), was approved by the State Drug Administration in February 2019 and became the first biologically similar drug approved for listing in China Hlx03 (adamumumab injection) and hlx02 (trastuzumab for injection) have also been accepted by the State Food and Drug Administration for new drug listing applications, and have been included in the priority review process Hlx02 has successively launched international multicenter phase 3 clinical trials in mainland China, Ukraine, EU Poland and the Philippines, becoming the first biosimilar drug to carry out international multicenter phase 3 clinical studies in China, and was accepted by the European Drug Administration in June 2019 In addition, orin1001, a small molecule innovative drug, has also obtained the qualification of FDA approval fast track Sinopharm group: 1.502 billion yuan In the first three quarters of 2019, the R & D expenses of Sinopharm group increased 63.99% over the same period of last year, accounting for 8.96% of the operating revenue In the first three quarters, its core varieties, enbip and tumor drug products continued to maintain strong growth Through self research and introduction, the company currently has more than 100 innovative drugs in its research products, including more than 50 macromolecular innovative drugs and more than 40 micromolecular innovative drugs   From the beginning of the year to November 13, the company has obtained the production approval documents of clopidogrel, tegrerolor, glutathione, metformin and dronedarone Ranitidine, cefadroxil, cefuroxime axetil, ibuprofen, enalapril and clindamycin passed the consistency evaluation It is expected that the amphotericin B complex, CD20 monoclonal antibody and mitoxantrone liposome will be listed in 2020, and PI3K will inhibit the growth of the liposome Preparations, RANKL monoclonal antibody, irinotecan liposome and other products are expected to be launched in 2021, dbpr108 (DPP-4), rmx1002 (EP4 receptor antagonist), long-term GLP-1 and other products are expected to be launched in 2022 According to statistics, there are more than 300 companies engaged in new drug research and development in China Hengrui, Qilu, Zhengda Tianqing and other large generic pharmaceutical enterprises are rapidly transforming to innovation, while a number of small R & D enterprises led by experts are also developing rapidly, becoming an important source of innovation and technology success China's pharmaceutical innovation industry is becoming more and more popular.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.